← Leaderboards
Danuta B Kozbor
Temple University
$4,215,757
Attributed
$6,917,597
Total exposure
8
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $4.1M · FY2005–19$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
Funding mix
By agency
NIH$6,917,597 · 8
By mechanism
U01$4,052,760 · 1
R21$2,693,037 · 6
R03$171,800 · 1
Top collaborators
- Andrea Gambotto2 shared
- Kunle O Odunsi2 shared
Others in their field
Top investigators on “Vaccinia Virus”
- George R Painter · Chimerix, Inc.$36,309,505
- Daniel F. Hoft · Saint Louis University$26,271,892
- Rama Rao Amara · Emory University$21,210,426
- David M. Margolis · University Of Texas Sw Med Ctr/Dallas$18,568,832
- Bertram L. Jacobs · Arizona State University-Tempe Campus$16,467,268
- Stewart H Shuman · Sloan-Kettering Institute For Cancer Res$15,348,129
Research focus
Vaccinia VirusTumorNeoplastic CellLaboratory MouseResponseHuman Immunodeficiency VirusVaccine DevelopmentRecombinantsVector VaccineAids VaccinesOncolytic VirusesClinical TrialsTumor-DerivedExhibitsToxic EffectDendritic CellsBlood VesselsDesignLesionCellsMediatingOncolyticCarbohydratesImmunization
Grant awards (17)
U01 Proposal Transfer - 2021$3,250,758
U01 · FY2019 · CA
Reprograming the tumor microenvironment to overcome multiple primary and acquired immune resistance mechanisms in ovarian cancer$802,002
U01 · FY2019 · CA
The role of CREB3L1 in synergy between oncolytic vaccinia virus and doxorubicin$85,900
R03 · FY2019 · CA · contact PI
The role of CREB3L1 in synergy between oncolytic vaccinia virus and doxorubicin$85,900
R03 · FY2018 · CA · contact PI
Oncolytic Viruses with Therapeutic Genes in the Treatment of Breast Cancer$220,696
R21 · FY2013 · CA · contact PI
Oncolytic Viruses with Therapeutic Genes in the Treatment of Breast Cancer$193,077
R21 · FY2012 · CA · contact PI
Enhancing Efficacy of Oncolytic Viriotherapy with PDT$238,172
R21 · FY2011 · CA · contact PI
Enhancing Efficacy of Oncolytic Viriotherapy with PDT$202,385
R21 · FY2010 · CA · contact PI
Gene Delivery Systems of Carbohydrate Mimotopes to Dendritic Cells$230,631
R21 · FY2009 · EB · contact PI
Gene Delivery Systems of Carbohydrate Mimotopes to Dendritic Cells$252,554
R21 · FY2008 · EB · contact PI
Impact of IL-21 on HIV Vaccine$253,872
R21 · FY2006 · AI · contact PI
Impact of IL-21 on HIV Vaccine$256,778
R21 · FY2005 · AI
Vaccine with altered HIV antigens$236,191
R21 · FY2003 · AI
Vaccine with altered HIV antigens$233,681
R21 · FY2002 · AI
MUCOSAL IMMUNITY TO HIV ENV BY ORAL VACCINATION$168,571
R21 · FY2001 · AI
MUCOSAL IMMUNITY TO HIV ENV BY ORAL VACCINATION$18,929
R21 · FY2001 · AI
MUCOSAL IMMUNITY TO HIV ENV BY ORAL VACCINATION$187,500
R21 · FY2000 · AI